The University of Michigan Pediatric Hemophilia and Coagulation Disorders Program, in partnership with the Indiana Hemophilia and Thrombosis Center (IHTC), invites qualified applicants for the 2018-2019 and 2019-2020 Fellowship Program in Hemostasis and Thrombosis. Pediatric hematology and oncology fellows in the final year of their clinical fellowship are invited to apply. This fellowship seeks to combine the unique strengths of the resources available at the University of Michigan and the IHTC. Fellows will have the opportunity to train under the mentorship of Dr. Steven Pipe and Dr. Amy Shapiro.
The objectives of the fellowship are: 1) to provide trainees with a major interest in a career in hematology focused training in clinical hemostasis and thrombosis, 2) to equip the postdoctoral trainees for independent, academic clinically-oriented careers in the field of hemostasis and thrombosis, and 3) to mentor post- doctoral trainees as skilled clinicians in the comprehensive care of individuals with bleeding and thrombotic disorders. The University of Michigan has a strong track record of successfully training leaders in coagulation disorders. To accomplish these goals, fellows will be involved in wide ranging clinical experiences, and have the opportunity to design and direct their own research project.
Theclinical experience, which is primarily at the C.S. Mott Children’s Hospital at the University of Michigan, will include management of patients with disorders of hemostasis and thrombosis within the inpatient and outpatient setting. Fellows will be appointed in the Department of Pediatrics at the Instructor level and will have attending physician privileges. They will play an active role in running a dedicated inpatient coagulation consult service. The outpatient service includes participating in multidisciplinary integrated care clinics within the hemophilia treatment center. The University of Michigan provides care for >150 pediatric patients with inherited bleeding disorders and >100 active pediatric thrombosis patients per year. The clinical program also includes a combined hematology and gynecology clinic for women and girls with bleeding and thrombotic disorders. Additionally, the fellow will receive training in the special coagulation laboratory, participating and interpreting assays under the supervision of the Special Coagulation Laboratory Director (Dr. Pipe).
Distinctiveopportunities available through the IHTC include outreach strategies and care of culturally diverse populations such as the Old Order Amish; treatment of patients with rare coagulation disorders; use of point of care ultrasound; standardization for planning of surgical procedures; design of quality assurance protocols; implementation of programs to standardize care; participation in national education programs (i.e. Partners); and design of and evaluation of center databases (i.e. surgery database).
The research experience can be tailored to the individual’s own experience, interests and goals. Investigators within the program conduct numerous research studies ranging from basic laboratory bench work to translational studies and clinical trials. Research strength at the University of Michigan is in the area of molecular mechanisms of hemophilia, structure-function of coagulation factor VIII, as well as research into genetic modifiers of hemostasis and thrombosis through murine and zebrafish genetic model systems. Clinical trial activities include investigator-initiated studies, projects conducted through the American Thrombosis and Hemostasis Network, pharmaceutical trials with novel therapeutics for hemophilia and Phase I-III human trials in gene therapy for hemophilia.
Please apply to Steven Pipe, MD, at email@example.com.
The Division of Pediatric Hematology/Oncology has an outstanding tradition of achievement in patient care and research in Pediatric Hematology/Oncology and Blood and Marrow Transplantation.
Our Program is renowned for our expertise in non-malignant hematology including leukocyte disorders - both number and function - coagulation disorders, and t...hrombosis. In addition, the members of the Division have provided unique services in the area of treatment of neuroblastoma, lymphomas, and brain tumors. National clinical research protocols have been developed at the University of Michigan for the treatment of refractory neuroblastoma, graft-versus-host-disease, and adaptive cellular therapy of leukemia and lymphoma using stem cell transplantation.
The Division is proud of the achievements in basic research including programs devoted towards understanding the biology of phagocytosis and generation of myeloid cells. Other research studies are designed to provide novel gene therapeutic approaches for treatment of hemophilia. Other research involves mechanisms of globin switching, pathogenesis of leukemia and neuroblastoma, immune therapy of leukemias, lymphomas, solid tumors, and B-cell signalling.
Our Division currently holds an NIH-supported Hematology Training Grant, which has been awarded to only three programs in the country. Additionally, the Division enjoys the largest continuing support from the National Institutes of Health within the Department of Pediatrics. A number of our faculty members have been recognized over the years by being selected as the Best Doctors in America .